(Total Views: 633)
Posted On: 10/30/2022 7:37:24 AM
Post# of 155802
Some thoughts about the news:
AMAREX and whomever should have been closely supervising them did a terrible job to put it mildly. We, the investors, have been misled (to put it mildly again) for many years now.
At the time I bought into CYDY for the HIV application, but I knew that the molecule was more (much more) than HIV and, sure enough, the HIV landscape has changed dramatically in the last 5 years. More drugs have come into the market making the competition much more difficult. I believe we still have a large niche in that we can simultaneously address the prevalence of NAFLD/NASH in the HIV community. I hope new management does not abandon this and neither the already proven effectiveness (in primates) of Leronlimab in PrEP and Dr. Sacha's efforts to find a cure, yes, a cure for this illness.
The future is now we are NASH and Oncology company practically (after abandoning the BLA for HIV) and philosophically. The implications??? We have a long road ahead with very large prize(s) at the end.
The task of efficiently lifting the holds while simultaneously designing and performing clinical trials efficiently while securing suitable financing is the priority now.
I hope new management is up to the task.
AMAREX and whomever should have been closely supervising them did a terrible job to put it mildly. We, the investors, have been misled (to put it mildly again) for many years now.
At the time I bought into CYDY for the HIV application, but I knew that the molecule was more (much more) than HIV and, sure enough, the HIV landscape has changed dramatically in the last 5 years. More drugs have come into the market making the competition much more difficult. I believe we still have a large niche in that we can simultaneously address the prevalence of NAFLD/NASH in the HIV community. I hope new management does not abandon this and neither the already proven effectiveness (in primates) of Leronlimab in PrEP and Dr. Sacha's efforts to find a cure, yes, a cure for this illness.
The future is now we are NASH and Oncology company practically (after abandoning the BLA for HIV) and philosophically. The implications??? We have a long road ahead with very large prize(s) at the end.
The task of efficiently lifting the holds while simultaneously designing and performing clinical trials efficiently while securing suitable financing is the priority now.
I hope new management is up to the task.
(18)
(0)
